Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In all the patients with systemic lupus erythematosus (SLE) tested in the active phase of the disease the serum interferon (IFN) level increases above the normal value (20 I.U./ml) reaching in some cases 80-160 I.U./ml. The detection of this increased level of IFN is useful to discriminate if some diseases such as glomerulonephritis or hemolytic anemias develop as part of a systemic auto-immune disorder since in such pathologic conditions lacking auto-immune mechanisms the serum IFN level is not increased. The detection of the serum IFN level proved to be a useful test in the follow-up of the clinical evolution as well as for the efficiency of the immunosuppressive therapy since in all the investigated cases IFN level decreased to normal after Cortisone administration concomitantly with the clinical remission of the disease. The above described data support the assumption that in the pathogeny of auto-immune diseases, SLE in our case, there are some initial cell-mediated auto-immune phenomena such as cell-mediated auto-cytotoxicity leading to a massive activation of the CTL and NK cells and consequently to the over-production of some lymphokines such as IFN.
 ...
PMID:Diagnostic value of serum interferon level in systemic lupus erythematosus. 244 30

A description is offered of a toxic and febrile young patient with diarrheic syndrome of twenty days evolution secondary to extranodal lymphoma of cecal location. A concomitant immunity deficit--selective IgA deficit--appeared in the form of chronic mucocutaneous candidiasis and discoid lupus, and in the absence of familial antecedents. As a result of this case study, an association of gastrointestinal lymphoma of unusual location with an underlying immune disorder, the literature was reviewed.
 ...
PMID:[Lymphoma of the cecum]. 266 Feb 7

Fifteen patients (9 females and 6 males) with the "lupus type" circulating anticoagulant have been studied. The underlying disease was an auto-immune disorder in 11 cases and a malignant hemopathy in 4 cases. The manifestations frequently associated with the lupus inhibitor, such as thrombosis, thrombocytopenia and false-positive VDRL test were analysed. Hemorrhagic syndrome occurred only when thrombocytopenia or acquired abnormality of Willebrand's factor was present. Thrombotic events (8 cases) were frequent. Deep venous thrombosis was complicated with pulmonary embolism in 4 patients. Platelet abnormality, decreased fibrinolytic response or acquired Willebrand's syndrome were found in all patients with a thrombotic event. These different manifestations followed diverging courses in some patients with persistent thrombocytopenia although the anticoagulant had disappeared in 3 cases, negativation of the false-positive VDRL test while the anticoagulant remained unchanged in 1 case, occurrence of a thromboembolic episode although the anticoagulant had disappeared in 1 case.
 ...
PMID:[Course of the manifestations associated with the antiprothrombinase circulating anticoagulant]. 293 5

An account is given of a case of hairy-cell leukaemia associated with a 'lupus-type' anticoagulant and a positive direct Coombs' test, both of which were clinically symptom free. This is yet another example of the coexistence of hairy-cell leukaemia and an auto-immune disorder, but the disorder in question has not been described previously.
 ...
PMID:Hairy-cell leukaemia associated with auto-immune disorders in the form of a 'lupus-type' anticoagulant and a positive direct Coombs' test. 309 37

Three children presenting with severe symptomatic bleeding episodes (one child developing a life-threatening subdural hematoma) due to acquired coagulation inhibitors are reported. In two patients, there was a history of an antecedent viral syndrome. None had evidence of drug exposure or an underlying immune disorder. All responded to the administration of corticosteroids, although one patient was steroid-dependent and required immunosuppressive therapy to achieve a complete response. Laboratory characteristics did not clearly distinguish the type of circulating inhibitor present in these children. Since bleeding was a prominent feature, we suggest that the inhibitors noted represent multiple specific coagulation factor inhibitors, rather than a "lupus-like" inhibitor which represents a common antibody to phospholipid-dependent coagulation tests. Such inhibitors may not be as benign as the common lupus anticoagulant seen in adult patients and should be considered in the child with symptomatic bleeding and a prolonged partial thromboplastin time. The true incidence and exact mechanism of action of acquired inhibitors in children has not been established.
 ...
PMID:Acquired symptomatic inhibitors of plasma clotting factors in nonhemophilic children. 374 Mar 68

A patient with systemic lupus erythematosus presented with clinical and histologic feature of urticarial vasculitis, a systemic immune disorder of unknown origin. This could represent a subset of collagen vascular disease.
 ...
PMID:Systemic lupus erythematosus appearing as an urticarial vasculitis. 377 Oct 41

Thirty-nine adults (34 male, 5 female) age 40 or under with squamous cell carcinoma of the head and neck (excluding nasopharyngeal carcinoma) were seen at the Baylor College of Medicine affiliated hospitals from 1964 to 1983. The average age of the patients was 36.3 years and they were nearly uniformly heavy smokers and drinkers. Twenty-six of the 39 patients were black. Lesions of the oral cavity and oropharynx were most frequent, followed by laryngeal lesions. Four patients presented with second primary tumors, and one patient had three separate lesions. Of the 39 patients, only 8 had cancers small enough to be considered curable by radiotherapy or organ-sparing surgery. The remainder of the patients required radical surgery (26), were considered incurable at the time of presentation (8), or refused treatment (3). Also noted was a relatively high incidence of prior trauma (gunshot wounds, laparotomies for trauma). Of 30 patients available for follow-up more than one year after treatment, 19 have died of their tumors. Only one patient had a documented immune disorder (systemic lupus). In contrast to previous authors, we conclude that the development of squamous cell carcinoma at a young age can be related to heavy smoking and drinking and that the poor survival in many patients is due to self-neglect and failure to seek medical care early in the course of the disease.
 ...
PMID:Squamous cell carcinoma of the oral cavity, pharynx, and larynx in young adults. 401 Apr 18

Drug-induced autoimmune diseases have two immunological peculiarities. Firstly, some autoantibodies are present, which are virtually never seen in spontaneous human diseases and may be regarded as specific. This applies to antimitochondria antibody type 3 (anti M3) in the lupus-like syndrome caused by Venocuran, to antimitochondria antibody type 6 (anti M6) in iproniazide-induced hepatitis, to anti-insulin antibody found after treatment with methimazole, and to anti liver/kidney microsome antibody type 2 (anti LKM2) associated with hepatitis induced by tielinic acid. Secondly, a search for other autoantibodies shows that the immune disorder is much more limited than in spontaneous autoimmune diseases. Thus, contrary to myasthenia and idiopathic autoimmune haemolytic anaemia, we never found autoantibodies specifically directed against the thyroid, the stomach or the adrenal gland during treatment with D-penicillamine and alpha-methyldopa. Only some hypotheses may account for these peculiarities. Cross-reaction between drug and autoantigen may occur, but the fact that the antigen-antibody reaction is not inhibited by the drug or its metabolites does not support this explanation. Much more attractive is the "T-cell bypass" theory, according to which autoreacting suppressor T-cells are circumvented by helper T-cells stimulated by the drug-modified autoantigen. In this case, the autoimmune reaction would indicate to which body substance the drug is bound, thus making it immunostimulant, and not a structural similarity between the drug and the autoantigen.
 ...
PMID:[Autoimmunity induced by drugs. Immunological characteristics and etiopathogenic hypotheses]. 624 48

The New Zealand Obese (NZO) mouse was studied as a potential model for autoimmune diabetes. NZO mice develop obesity, glucose intolerance, and insulin resistance, and have low-titer IgM antibodies to the insulin receptor. It is shown that they have circulating antibodies to both native DNA and denatured, single-stranded DNA. The antibody levels are higher in females, and, up to 6 mo of age, are comparable to those found in the related NZB X NZW F1 (NZB/W) mouse, a model for systemic lupus erythematosus. After 6 mo of age the antibody levels in NZO mice fall toward normal, in contrast to the persistently elevated levels in NZB/W mice. NZB/W mice are known to succumb to immune complex-mediated proliferative glomerulonephritis before 1 yr of age, whereas NZO mice survive. NZO kidneys exhibit light microscopic features of both diabetic and lupus nephropathies: glomerular proliferation, mesangial deposits, mild basement membrane thickening, glomerulosclerosis, eosinophilic nodules in some glomeruli, occasional hyalinization of the glomerular arterioles, and healing arteriolar inflammation. These changes are associated with glomerular deposition of immunoglobulin, especially IgM, in a granular pattern on fluorescent staining. The NZO mouse, therefore, has evidence of a generalized immune disorder and provides a model for studying the relationship between autoimmunity, obesity, and diabetes.
 ...
PMID:Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse. 700 65

Peyronie's disease (induratio penis plastica) and a syndrome resembling systemic lupus erythematosus (S.L.E.) contemporaneously developed in a 50-year-old man six months after initiation of treatment with metoprolol. In view of the improvement in symptoms and signs on withdrawal of metoprolol, it seems likely that the drug was responsible for both these conditions. Peyronie's disease has been observed in relation to treatment with other adrenergic blocking agents, including practolol, and the S.L.E. syndrome is thought to be a possible untoward effect of practolol therapy. The relationship between practolol and sclerosing conditions elsewhere in the body is well recognized and an immunological basis for the fibrosis has been suggested. Similarly, the possibility is raised that Peyronie's disease may be in this case a particular expression of the auto immune disorder induced by metoprolol administration.
 ...
PMID:Peyronie's disease and systemic lupus erythematosus syndrome associated with metoprolol administration: a case report. 732 18


1 2 3 4 Next >>